These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36465958)

  • 1. Classic psychedelics, health behavior, and physical health.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    Ther Adv Psychopharmacol; 2022; 12():20451253221135363. PubMed ID: 36465958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classic Psychedelics and Human-Animal Relations.
    Pöllänen E; Osika W; Stenfors CUD; Simonsson O
    Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic psychedelic use and current meditation practice.
    Simonsson C; Chambers R; Hendricks PS; Goldberg SB; Osika W; Schlosser M; Ryde A; Christersson E; Simonsson O
    Mindfulness (N Y); 2023 Apr; 14(4):763-768. PubMed ID: 37693239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and associations of classic psychedelic-related seizures in a population-based sample.
    Simonsson O; Goldberg SB; Chambers R; Osika W; Long DM; Hendricks PS
    Drug Alcohol Depend; 2022 Oct; 239():109586. PubMed ID: 35981469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    J Affect Disord; 2023 Apr; 326():105-110. PubMed ID: 36720405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationships of classic psychedelic use with criminal behavior in the United States adult population.
    Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G
    J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.
    Simonsson O; Stenfors CUD; Goldberg SB; Hendricks PS; Osika W
    Front Psychol; 2023; 14():1151626. PubMed ID: 37476092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    Sexton JD; Nichols CD; Hendricks PS
    Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.
    Zeifman RJ; Singhal N; Breslow L; Weissman CR
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):436-451. PubMed ID: 33860173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic use and psychiatric risks.
    Simonsson O; Goldberg SB; Chambers R; Osika W; Simonsson C; Hendricks PS
    Psychopharmacology (Berl); 2023 Oct; ():. PubMed ID: 37874345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
    Hendricks PS; Thorne CB; Clark CB; Coombs DW; Johnson MW
    J Psychopharmacol; 2015 Mar; 29(3):280-8. PubMed ID: 25586402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.